# Judith M. Bliss

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/judith-m-bliss/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,430 |
| Field | Breast Cancer Treatment Studies |
| h-index | 91 |
| i10-index | 244 |
| Last Known Institution | Institute of Cancer Research |
| OpenAlex ID | https://openalex.org/A5006665510 |
| ORCID iD | https://orcid.org/0000-0001-7957-7424 |
| Works | 806 |

## Researcher papers

- [A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-exemestane-after-two-to-three-years-of-tamoxifen-therapy/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial](https://scholariq.org/papers/hypofractionated-breast-radiotherapy-for-1-week-versus-3-weeks-fast-forward-5/)
- [Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial](https://scholariq.org/papers/survival-and-safety-of-exemestane-versus-tamoxifen-after-2-3-years-tamoxifen/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative](https://scholariq.org/papers/genomic-and-transcriptomic-analyses-of-breast-cancer-primaries-and-matched/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Institute of Cancer Research](https://scholariq.org/institutions/institute-of-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.